Back to search

Article

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic Center

2023-05-09

Abstract excerpt

The prognosis of patients with recurrent or metastatic of the head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is severe and, consequently, the identification of therapeutic options for this category of patients is a priority. Nivolumab, an anti- programmed cell death protein 1 (anti-PD-1) monoclonal antibody, has been approved for the treatment of recurrent or metastatic HNS...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b7f110fb-5242-59dd-8a54-a3875b1dd309
DOI
10.20944/preprints202305.0561.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic CenterDOI 10.20944/preprints202305.0561.v1
Clinical characteristics and prognostic analysis of 95 cases of recurrent/metastatic nasopharyngeal carcinoma treated with immunotherapy: a single-center retrospective studySemantic proximity
Combination of immunotherapy and anti-EGFR agents in immunotherapy refractory head neck cancer recurrent and metastatic head neck squamous cell carcinomaSemantic proximity
Multicenter validation of an assay to predict anti-PD-1 disease control in patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma: The PREDAPT StudySemantic proximity
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.Semantic proximity
Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients.Semantic proximity
Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity
Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.Semantic proximity
Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome expression could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti–programmed cell death 1 monotherapySemantic proximity
Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.Semantic proximity
High-Sensitivity PD-L1 Staining Using Clone 73-10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial neoplasia, and Squamous Cell Carcinoma of Head and NeckSemantic proximity
Stage IV Non-small Cell Lung Adenocarcinoma in Complete Response for 5 Years Post-first-line Nivolumab Immunotherapy: Are We Talking about a Cure?Semantic proximity
Analysis of high-risk factors and prognosis of early relapse in 104 patients with natural killer/T-cell lymphoma: a single-center retrospective studySemantic proximity
Select a neighboring publication to make it the new centre.